---
layout: minimal-medicine
title: Midostaurin
---

# Midostaurin
### Generic Name
Midostaurin

### Usage
Midostaurin is a kinase inhibitor primarily used in combination with other chemotherapy drugs to treat certain types of cancer. Its main application is in the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that's positive for a specific FLT3 mutation (detected by an FDA-approved test).  The drug is also indicated for treating adult patients with mast-cell leukemia and aggressive systemic mastocytosis (or systemic mastocytosis with associated hematological neoplasm).  It's crucial to understand that Midostaurin is not used alone as an induction therapy for AML; it's always part of a combination regimen.

### Dosage
Dosage varies significantly based on the specific cancer being treated and the patient's overall health.  It's always administered orally (as capsules).

**Acute Myeloid Leukemia (AML), FLT3-positive:**

* **Induction:** 50 mg twice daily (BID) from days 8-21 of each induction cycle, in conjunction with daunorubicin and cytarabine. A second induction cycle may be necessary depending on the clinical response.
* **Consolidation:** 50 mg BID from days 8-21 of each 28-day consolidation cycle,  combined with high-dose cytarabine.  This is typically administered for 4 cycles.
* **Maintenance (off-label):** 50 mg BID from days 1-28 of each 28-day cycle for up to 12 cycles, or until relapse.

**Mast-cell leukemia and Systemic Mastocytosis:**

* 100 mg BID until the disease progresses or intolerable side effects occur.


**Dosage Adjustments:**  Dosage adjustments are not routinely specified for mild to moderate hepatic or renal impairment; however, close monitoring is crucial.  Severe impairment requires careful consideration and potentially different treatment strategies.  Dose reductions and interruptions may be necessary based on the severity of side effects, particularly hematologic toxicity (low blood cell counts).  Consult the prescribing information for detailed guidelines on managing toxicity.

**Pediatric Dosage:** The safety and effectiveness of Midostaurin have not been established in pediatric patients.

### Side Effects
Midostaurin, like many cancer therapies, can cause a range of side effects.  The frequency and severity vary between individuals.

**Common Side Effects (>10%):**

* Headache
* Fatigue
* Dizziness
* Insomnia
* Edema (swelling)
* QT prolongation (on ECG)
* Nausea
* Vomiting
* Mucositis (mouth sores)
* Diarrhea
* Increased lipase and amylase levels (blood enzymes)
* Abdominal pain
* Constipation
* Skin rash
* Hyperhidrosis (excessive sweating)
* Hyperglycemia (high blood sugar)
* Hypocalcemia (low blood calcium)
* Hyperuricemia (high uric acid)
* Increased gamma-glutamyl transferase (liver enzyme)
* Various electrolyte imbalances (sodium, potassium, magnesium, phosphate)
* Urinary tract infections
* Febrile neutropenia (fever with low neutrophil count)
* Lymphocytopenia (low lymphocyte count)
* Leukopenia (low white blood cell count)
* Anemia (low red blood cell count)
* Thrombocytopenia (low platelet count)
* Increased liver enzymes (ALT, AST, ALP)
* Hyperbilirubinemia (high bilirubin)
* Musculoskeletal pain
* Arthralgia (joint pain)
* Increased serum creatinine (kidney function marker)
* Upper respiratory tract infections
* Cough
* Dyspnea (shortness of breath)
* Pleural effusion (fluid around the lungs)
* Fever


**Less Common, but Serious Side Effects:**  These include severe allergic reactions (anaphylaxis), interstitial lung disease or pneumonitis, cardiac events (heart failure, myocardial infarction), and severe gastrointestinal bleeding.


**Important Note:** If you experience any concerning side effects, contact your healthcare provider immediately.


### How it Works
Midostaurin is a multi-targeted tyrosine kinase inhibitor.  This means it blocks the activity of several protein kinases, enzymes that play a role in cell growth and division. Specifically, it targets:

* FLT3 (both wild-type and mutated forms):  FLT3 mutations are common in AML and contribute to uncontrolled cell growth. Midostaurin's inhibition of FLT3 helps to slow or stop this growth.
* KIT (wild-type and D816V mutant): KIT is a crucial kinase in mast cells.  Its inhibition is critical for treating mast-cell leukemia and systemic mastocytosis.
* Other kinases: Midostaurin also inhibits other kinases like PDGFR alpha/beta and members of the protein kinase C (PKC) family, further contributing to its anti-cancer effects.

By inhibiting these kinases, Midostaurin disrupts cancer cell signaling pathways, leading to reduced cell growth, increased cell death (apoptosis), and potentially improved treatment outcomes.

### Precautions
* **Hypersensitivity:** Midostaurin is contraindicated in patients with known hypersensitivity to the drug or its components.
* **Drug Interactions:**  Strong CYP3A4 inhibitors (e.g., certain antifungal and antiviral drugs) can increase Midostaurin levels, increasing the risk of side effects. Conversely, strong CYP3A4 inducers (e.g., St. John's Wort) can decrease Midostaurin levels, potentially reducing its effectiveness. Grapefruit juice can also significantly impact Midostaurin levels.
* **Pregnancy and Breastfeeding:** Midostaurin is known to cause fetal harm and should be avoided during pregnancy. Effective contraception is mandatory for both men and women during treatment and for at least four months afterward. Breastfeeding is not recommended during treatment or for at least four months post-treatment.
* **Pulmonary Toxicity:**  Close monitoring for signs and symptoms of pulmonary toxicity (interstitial lung disease, pneumonitis) is essential.
* **Hematologic Toxicity:** Regular blood tests to monitor blood cell counts are necessary to detect and manage potential hematologic toxicity (anemia, neutropenia, thrombocytopenia).
* **QT Prolongation:** Midostaurin can prolong the QT interval on electrocardiograms (ECGs), increasing the risk of serious heart rhythm disturbances.  This is particularly relevant in patients with pre-existing heart conditions or those taking other medications that prolong the QT interval.


### FAQs

* **Q: Can I take Midostaurin with other medications?** A:  Discuss all medications (including over-the-counter drugs and herbal supplements) with your doctor or pharmacist before starting Midostaurin.  Some drugs may interact significantly, impacting either Midostaurin's effectiveness or increasing the risk of side effects.
* **Q: How should I store Midostaurin?** A: Store Midostaurin capsules at room temperature, away from moisture and direct sunlight.
* **Q: What should I do if I miss a dose?** A: Do not take a double dose to make up for a missed dose.  Simply take the next dose as scheduled.
* **Q: How long will I need to take Midostaurin?** A: The duration of treatment varies based on the type of cancer, response to treatment, and the presence of side effects. Your doctor will determine the optimal treatment duration.
* **Q: Are there specific dietary restrictions while taking Midostaurin?** A: Avoid grapefruit juice due to its potential interaction with the medication.  Consult your doctor for any other specific dietary advice.
* **Q: What are the long-term effects of Midostaurin?** A: Long-term effects vary widely depending on the individual and the duration of treatment. Regular follow-up with your oncologist is important to monitor for potential late-onset effects.

**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.  The information provided here is not exhaustive and should not replace the detailed prescribing information provided by the manufacturer.
